57th ASH Annual Meeting and Exposition (December 5-8, 2015): 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Novel Therapies and Targets in Lymphoma

Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents Oral and Poster Abstracts
Oral

Tangerine 1 (WF1), Level 2 (Orange County Convention Center)

Moderators:

Rosa Lapalombella, PhD, The Ohio State University and Mathias Witzens-Harig, MD, University Hospital Heidelberg

Disclosures:

No relevant conflicts of interest to declare.

10:30 AM

589

Genome-Wide Mapping Reveals BRD4 in Regulation of Tumor-Driver Genes in Cutaneous T-Cell Lymphoma

Anjali Mishra, Ph.D.¹, Alex Hartlage, BS¹, Laura Sullivan²^*, Leah Grinshpun²^*, Sonya Kwiatkowski²^*, Jun Qi, PhD³^*, James E. Bradner, MD^4,5, Pierluigi Porcu, MD^6,7 and Michael A. Caligiuri, MD¹

¹The Ohio State University Comprehensive Cancer Center, Columbus, OH
²The Ohio State University Comprehensive Cancer Center, Columbus
³Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁵Harvard Medical School, Boston, MA
⁶The Ohio State University Wexner Medical Center, Columbus, OH
⁷Division of Hematology, The Ohio State University, Columbus, OH

10:45 AM

590

Targeting the X-Linked Inhibitor of Apoptosis Protein (XIAP) Can Promote Tumor Cell Death, and Increase the Cytotoxic Effects of Chemotherapy Agents in in Vitro and In Vivo Models of Rituximab-Resistant Lymphoma

Kyle L. Runckel, BS¹, Cory Mavis, MSc²^*, Joseph Skitzki³^*, Juan J Gu, PhD²^*, Francisco J. Hernandez-Ilizaliturri, MD⁴ and Myron S. Czuczman, MD⁵

¹Medicine, Roswell Park Cancer Institute, Buffalo, NY
²Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, NY
³Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY
⁴Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY
⁵Celgene Corporation, Summit, NJ

11:00 AM

591

All-Trans Retinoic Acid and Interferon-Alpha Increase CD38 Expression on Adult T-Cell Leukemia Cells and Sensitize Them to T Cells Bearing Anti-CD38 Chimeric Antigen Receptors

Keichiro Mihara, MD, PhD¹, Tetsumi Yoshida, MD¹^*, Seiko Ishida, MD, PhD¹^*, Yoshifumi Takei, MD, PhD²^*, Akira Kitanaka, MD, PhD³, Kazuya Shimoda, MD, PhD³, Kazuhiro Morishita, MD, PhD⁴^*, Yoshihiro Takihara, MD, PhD⁵ and Tatsuo Ichinohe, MD⁶

¹Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
²Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan
³Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
⁴Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, Faculty of Medicine, Miyazaki University, Miyazaki, Japan
⁵Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
⁶Hiroshima University, Hiroshima, Japan

11:15 AM

592

Targeting the Hsp90 Oncoproteome in Burkitt Lymphoma

Lisa Giulino Roth, MD^1,2, Herman van Besien³^*, Anna Rodina, PhD⁴^*, Tony Taldone, PhD⁵^*, Hediye Erdjument-Bromage, PhD⁶^*, Matthew J. Barth, MD⁷, Gabriela Chiosis, PhD⁵^* and Ethel Cesarman¹

¹Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY
²Pediatrics, Weill Cornell Medical College, New York, NY
³Weill Cornell Medical College, New York, NY
⁴Memorial Sloan Kettering Cancer Center, New York, NY
⁵Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY
⁶New York University, New York, NY
⁷Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, NY

11:30 AM

593

Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas

Changchun Deng, MD, PhD¹, Mark Lipstein¹^*, Luigi Scotto, PhD¹^*, Yun Hao²^*, Nicholas P. Tatonetti, PHD²^*, Michael Mangone, PhD¹^*, Shirong Li, PhD³^*, Suzanne Lentzsch³, Ronald B. Realubit, PHD⁴^*, Charles Karan Jr., PHD⁴^* and Owen A. O'Connor, MD, PhD¹

¹Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY
²Department of Biomedical Informatics, Columbia University Medical Center, New York, NY
³Division of Hematology/Oncology, Columbia University, New York, NY
⁴Department of Systems Biology, Columbia University Medical Center, New York

11:45 AM

594

SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies

Maureen C. Ryan, PhD^*, Brian Schimpf^*, Martha Anderson^*, Weiping Zeng^*, Kim Emmerton^*, Jamie Miyamoto^*, Heather Kostner^*, Changpu Yu^*, Heather Van Epps, PhD^*, Laurie Tatalick, DVM, PhD, DACVP^* and Dennis Benjamin, PhD^*

Translational Research, Seattle Genetics, Inc., Bothell, WA

See more of: Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

625.O3.6 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Novel Therapies and Targets in Lymphoma